Mer­ck­'s 15-strain pneu­mo­nia shot match­es Pre­vnar 13 in late-stage in­fant study, but Pfiz­er's next-gen shot looms

In or­der to keep the heat on Pfiz­er and its next-gen­er­a­tion pneu­mo­coc­cal vac­cine, Mer­ck knows it will need to get cre­ative to give its 15-serotype shot a fight­ing chance. In­fant pa­tients could hold the key, and new da­ta con­tin­ue to sup­port Mer­ck’s case there.

Mer­ck’s Vaxneu­vance, a next-gen, 15-va­lent shot, matched Pfiz­er’s block­buster Pre­vnar 13 in terms of dri­ving im­muno­genic­i­ty across 13 shared serotypes and on the safe­ty front, ac­cord­ing to da­ta from the Phase III PNEU-PED study re­vealed Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER